IN2014DN07888A - - Google Patents
Info
- Publication number
- IN2014DN07888A IN2014DN07888A IN7888DEN2014A IN2014DN07888A IN 2014DN07888 A IN2014DN07888 A IN 2014DN07888A IN 7888DEN2014 A IN7888DEN2014 A IN 7888DEN2014A IN 2014DN07888 A IN2014DN07888 A IN 2014DN07888A
- Authority
- IN
- India
- Prior art keywords
- nanostructures
- cells
- compositions
- cases
- conditions
- Prior art date
Links
- 210000004027 cell Anatomy 0.000 abstract 7
- 239000002086 nanomaterial Substances 0.000 abstract 6
- 239000000203 mixture Substances 0.000 abstract 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 102000015779 HDL Lipoproteins Human genes 0.000 abstract 2
- 108010010234 HDL Lipoproteins Proteins 0.000 abstract 2
- 208000003950 B-cell lymphoma Diseases 0.000 abstract 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000004941 influx Effects 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 230000004060 metabolic process Effects 0.000 abstract 1
- 102000014452 scavenger receptors Human genes 0.000 abstract 1
- 108010078070 scavenger receptors Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nanotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Ceramic Engineering (AREA)
- Diabetes (AREA)
- Optics & Photonics (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261601706P | 2012-02-22 | 2012-02-22 | |
| PCT/US2013/027431 WO2013126776A1 (en) | 2012-02-22 | 2013-02-22 | Nanostructures for treating cancers and other conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN07888A true IN2014DN07888A (enExample) | 2015-04-24 |
Family
ID=47833440
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN7888DEN2014 IN2014DN07888A (enExample) | 2012-02-22 | 2013-02-22 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20150064255A1 (enExample) |
| EP (2) | EP2817024B1 (enExample) |
| JP (1) | JP2015513543A (enExample) |
| KR (1) | KR20140123597A (enExample) |
| CN (1) | CN104244965A (enExample) |
| AU (1) | AU2013222238A1 (enExample) |
| CA (1) | CA2865279C (enExample) |
| ES (1) | ES2745208T3 (enExample) |
| IN (1) | IN2014DN07888A (enExample) |
| MX (1) | MX2014010161A (enExample) |
| WO (1) | WO2013126776A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1879606B1 (en) | 2005-04-25 | 2013-06-12 | Massachusetts Institute of Technology | Self-assembling peptides for promoting hemostasis |
| CN101472620A (zh) | 2006-04-25 | 2009-07-01 | 麻省理工学院 | 用于影响污染物、机体流体或其它实体移动和/或影响其它生理状况的组合物和方法 |
| JP5539962B2 (ja) | 2008-04-25 | 2014-07-02 | ノースウェスタン、ユニバーシティ | コレステロールを隔離するのに適したナノ構造体 |
| US9439941B2 (en) | 2009-12-14 | 2016-09-13 | The University Of Hong Kong | Nano cancer barrier device (NCBD) to immobilize and inhibit the division of metastic cancer stem cells |
| CA2787156C (en) | 2010-01-19 | 2020-12-29 | Northwestern University | Synthetic nanostructures for delivery of oligonucleotides |
| DE12722942T1 (de) | 2011-03-31 | 2021-09-30 | Modernatx, Inc. | Freisetzung und formulierung von manipulierten nukleinsäuren |
| SI2791160T1 (sl) | 2011-12-16 | 2022-07-29 | Modernatx, Inc. | Sestave modificirane MRNA |
| SMT202200337T1 (it) | 2012-11-26 | 2022-09-14 | Modernatx Inc | Rna modificato al livello del terminale |
| AU2013374345A1 (en) | 2013-01-17 | 2015-08-06 | Moderna Therapeutics, Inc. | Signal-sensor polynucleotides for the alteration of cellular phenotypes |
| EP2971010B1 (en) | 2013-03-14 | 2020-06-10 | ModernaTX, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
| ES2750608T3 (es) | 2013-07-25 | 2020-03-26 | Exicure Inc | Construcciones esféricas a base de ácido nucleico como agentes inmunoestimulantes para uso profiláctico y terapéutico |
| US10568898B2 (en) | 2013-08-13 | 2020-02-25 | Northwestern University | Lipophilic nanoparticles for drug delivery |
| US10413565B2 (en) | 2014-04-30 | 2019-09-17 | Northwestern University | Nanostructures for modulating intercellular communication and uses thereof |
| WO2016011049A2 (en) * | 2014-07-14 | 2016-01-21 | Schwendeman Anna | Compositions and methods for disease treatment using nanoparticle delivered compounds |
| CN107002081A (zh) | 2014-10-06 | 2017-08-01 | 埃克西奎雷股份有限公司 | 抗tnf化合物 |
| US10517924B2 (en) * | 2014-11-24 | 2019-12-31 | Northwestern University | High density lipoprotein nanoparticles for inflammation |
| US10307491B2 (en) | 2015-01-30 | 2019-06-04 | The Regents Of The University Of Michigan | Liposomal particles comprising biological molecules and uses thereof |
| US10078092B2 (en) | 2015-03-18 | 2018-09-18 | Northwestern University | Assays for measuring binding kinetics and binding capacity of acceptors for lipophilic or amphiphilic molecules |
| EP3273944B1 (en) | 2015-03-25 | 2024-11-20 | The Regents of The University of Michigan | Compositions and methods for delivery of biomacromolecule agents |
| US10967072B2 (en) | 2016-04-27 | 2021-04-06 | Northwestern University | Short interfering RNA templated lipoprotein particles (siRNA-TLP) |
| US12257352B2 (en) | 2016-06-20 | 2025-03-25 | The Regents Of The University Of Michigan | Compositions and methods for delivery of biomacromolecule agents |
| JP7546927B2 (ja) * | 2019-01-24 | 2024-09-09 | ノースウェスタン ユニバーシティ | 脂質結合体化コア足場を使用する高密度リポタンパク質模倣ナノ粒子 |
| EP3958843A4 (en) * | 2019-04-26 | 2023-02-22 | Northwestern University | HIGH DENSITY LIPOPROTEIN NANOPARTICLES AND RNA TEMPLATED LIPOPROTEIN PARTICLES FOR EYE THERAPY |
| WO2020231860A1 (en) * | 2019-05-10 | 2020-11-19 | Northwestern University | Orally delivered lipid nanoparticles target and reveal gut cd36 as a master regulator of systemic lipid homeostasis with differential gender responses |
| CN115003312A (zh) * | 2019-09-18 | 2022-09-02 | 西北大学 | 作为癌症中铁死亡诱导物的高密度脂蛋白样纳米颗粒 |
| CN112569207A (zh) * | 2019-09-30 | 2021-03-30 | 复旦大学 | 一种载脂蛋白修饰的仿生纳米肿瘤疫苗及其制备方法和用途 |
| KR102614058B1 (ko) * | 2022-06-13 | 2023-12-15 | (주) 멥스젠 | 약물전달용 재구축 고밀도 지단백 나노입자 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007212700A1 (en) * | 2006-01-26 | 2007-08-16 | University Of Massachusetts | RNA interference agents for therapeutic use |
| US20110020242A1 (en) * | 2007-12-12 | 2011-01-27 | Gang Zheng | High-density lipoprotein-like peptide-phospholipid scaffold ("hpps") nanoparticles |
| JP5539962B2 (ja) | 2008-04-25 | 2014-07-02 | ノースウェスタン、ユニバーシティ | コレステロールを隔離するのに適したナノ構造体 |
| CA2787156C (en) * | 2010-01-19 | 2020-12-29 | Northwestern University | Synthetic nanostructures for delivery of oligonucleotides |
-
2013
- 2013-02-22 AU AU2013222238A patent/AU2013222238A1/en not_active Abandoned
- 2013-02-22 IN IN7888DEN2014 patent/IN2014DN07888A/en unknown
- 2013-02-22 EP EP13708044.6A patent/EP2817024B1/en active Active
- 2013-02-22 US US14/380,406 patent/US20150064255A1/en not_active Abandoned
- 2013-02-22 MX MX2014010161A patent/MX2014010161A/es unknown
- 2013-02-22 CA CA2865279A patent/CA2865279C/en active Active
- 2013-02-22 ES ES13708044T patent/ES2745208T3/es active Active
- 2013-02-22 EP EP19175659.2A patent/EP3597209A1/en not_active Withdrawn
- 2013-02-22 WO PCT/US2013/027431 patent/WO2013126776A1/en not_active Ceased
- 2013-02-22 CN CN201380017827.7A patent/CN104244965A/zh active Pending
- 2013-02-22 JP JP2014558893A patent/JP2015513543A/ja active Pending
- 2013-02-22 KR KR1020147025926A patent/KR20140123597A/ko not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| US20150064255A1 (en) | 2015-03-05 |
| JP2015513543A (ja) | 2015-05-14 |
| WO2013126776A1 (en) | 2013-08-29 |
| KR20140123597A (ko) | 2014-10-22 |
| EP3597209A1 (en) | 2020-01-22 |
| EP2817024A1 (en) | 2014-12-31 |
| CA2865279C (en) | 2023-04-25 |
| CN104244965A (zh) | 2014-12-24 |
| EP2817024B1 (en) | 2019-07-10 |
| MX2014010161A (es) | 2015-03-09 |
| AU2013222238A1 (en) | 2014-09-18 |
| ES2745208T3 (es) | 2020-02-28 |
| CA2865279A1 (en) | 2013-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN07888A (enExample) | ||
| PH12012502399A1 (en) | Combination therapy methods for treating proliferative diseases | |
| MX2010004857A (es) | Compuestos de benzodiazepinona utiles en el tratamiento de afecciones de la piel. | |
| PH12014501351B1 (en) | Fluorinated estrogen receptor modulators and uses thereof | |
| CA2865011C (en) | Methods and compositions for treating huntington's disease | |
| NZ709215A (en) | Compositions comprising anti-cd38 antibodies and lenalidomide | |
| WO2010132697A3 (en) | Methods and compositions for treatment | |
| PH12012502380B1 (en) | Methods of treatment of pancreatic cancer | |
| SG10201907588XA (en) | Androgen Receptor Modulators And Uses Thereof | |
| PH12013500481A1 (en) | Estrogen receptor modulators and uses thereof | |
| PH12012502419A1 (en) | Estrogen receptor modulators and uses thereof | |
| IN2015KN00414A (enExample) | ||
| PH12015500879A1 (en) | Compositions and methods for treating proteinopathies | |
| PH12014502095A1 (en) | Estrogen receptor modulators and uses thereof | |
| PE20150223A1 (es) | Anticuerpos antagonistas mejorados contra factor-8 de crecimiento y diferenciacion y usos de los mismos | |
| MX362185B (es) | Composiciones y tratamiento para enfermedades y trastornos del ojo. | |
| MX370721B (es) | Compuestos y composiciones novedosas para atacar las células madre del cáncer. | |
| GB201318761D0 (en) | Compounds for the treatment of neuropsychiatric disorders | |
| WO2012170947A3 (en) | Methods for modulating factor 12 expression | |
| DK2714888T3 (da) | Rekombinant gær | |
| IN2014CN03610A (enExample) | ||
| MX359210B (es) | Composición de combinación de pac-1 y tamoxifeno. | |
| MX2013013649A (es) | Compuestos de quinona para tratar enfermedades mediadas por ape1. | |
| MX2016008221A (es) | Composiciones prebioticas para el cuidado oral que contienen un alquilglucosido. | |
| PH12014500536A1 (en) | Compositions and methods for treating cancer using pi3k beta inhibitor and mapk pathway inhibitor, including mek and raf inhibitors |